The murine monoclonal antibody A33 (mAbA33) recognises a human cell membrane-associated antigen selectively expressed in epithelial cells of the lower gastrointestinal tract and > 90% of colonic cancers, but is not detected in a wide range of other normal tissues by immunohistochemical analysis. In phase I/II clinical triasl, mAbA33 has been shown to target advanced colon cancers and the humanized version is currently being evaluated in therapy studies. Although the mAbA33 has been well characterised by immunohistochemical and clinical studies, until recently, the target antigen has remained poorly defined. This was largely attributable to the antigenic determinant recognised by mAbA33 being dependent on the native spatial conformation of the A33 antigen which impeded its identification by conventional two-dimensional electrophoresis (2-DE) and immunoblot analysis. We have developed an immunoblot method, based on nonreducing/non-urea precast 2-DE gels, that has facilitated the purification of the detergent (0.3% Triton X-100) solubilised A33 antigen from the human colon cancer cell lines LIM1215 and SW1222. Under these 2-DE conditions, the A33 antigen electrophoreses with an apparent M(r) approximately 41000 and pI 5.0-6.0. Attempts to isolate the A33 antigen from 2-DE gels for direct structural analysis were unsuccessful, due to its co-electrophoresis with actin and cytokeratin proteins. However, using Western blot and biosensor detection the A33 antigen has been purified chromatographically and N-terminal sequence analysis was possible. Using polyclonal antibodies raised against a synthetic peptide corresponding to the N-terminal region of the A33 antigen we have used Western blot analysis to localise the molecule in our master 2-DE protein database for normal human colon crypts and several colon carcinoma cell lines (URL address: http:(/)/www.ludwig.edu.au). Under reducing 2-DE conditions, the A33 antigen electrophoresis as 6 differentially charged isoforms (pI 4.6-4.8) with a single molecular weight species at M(r) approximately 55000.

Download full-text PDF

Source
http://dx.doi.org/10.1002/elps.1150180345DOI Listing

Publication Analysis

Top Keywords

a33 antigen
28
antigen
10
a33
9
monoclonal antibody
8
antibody a33
8
2-de gels
8
human colon
8
cell lines
8
2-de conditions
8
conditions a33
8

Similar Publications

Article Synopsis
  • * The study focused on JEN-101, a localized injection of interleukin-12 designed to boost immune response in dogs with advanced melanoma, evaluating its safety, effectiveness, and immune effects over several doses.
  • * Results indicated that JEN-101 was well-tolerated with manageable side effects, and it showed promising biological responses, suggesting its potential for further research and relevance to human cancer treatment.
View Article and Find Full Text PDF
Article Synopsis
  • NMOSD is a rare autoimmune disease affecting the CNS, and this study is the first Phase I clinical trial in Chinese patients testing the safety and efficacy of a new drug called BAT4406F, an anti-CD20 monoclonal antibody.
  • The study involved 15 patients who received different doses of BAT4406F, with results showing no dose-limiting toxicities and mostly mild side effects, indicating a favorable safety profile.
  • The drug demonstrated effective B-cell depletion, important for treating NMOSD, with a nonlinear pharmacokinetic profile and longer elimination half-life, suggesting promising therapeutic potential.
View Article and Find Full Text PDF

Purpose: HLA-A29 is the main susceptibility factor for birdshot chorioretinitis (BSCR). Our study assessed the impact of the second HLA-A allele alongside HLA-A29 on BSCR severity and susceptibility, focusing on HLA-A29 homozygous patients and those with alleles from the HLA-Aw19 group.

Methods: We included 120 additional cases to our previous analysis of 286 patients with BSCR, all HLA-A29 positive.

View Article and Find Full Text PDF

Although not as lethal as variola virus (VARV), the cause of smallpox, monkeypox virus (MPXV) represents a threat to public health, with important infection rates and mortality in several African countries and signs of spreading worldwide. MPXV may establish new reservoirs in non-endemic countries and can be considered a possible biological weapon. Human-to-human MPXV transmission is increasing with a growing susceptibility, coincident with the declining herd immunity against smallpox.

View Article and Find Full Text PDF
Article Synopsis
  • * Out of 18 postmenopausal women treated, 66% showed an objective response, and common side effects included fatigue and hypertension, but no severe toxicities were reported.
  • * The research also highlighted changes in biomarker levels and gene expression after treatment, indicating potential biological impacts of combining antiangiogenic therapy with hormone therapy in this patient population.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!